Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: BoredMember who wrote (9494)	12/20/2017 9:48:20 PM
From: cacmed	Respond to of 12873

I have always agreed with your point of view that they are doing their best. The question now revolves around the facts that they are not the only ones trying this approach. The other actors seem to be working in traditional scientific collaborations with extensive financial and laboratory assets. Twelve years ago it might have been a great adventure to forge a trail where no one else was going. Anil's one man approach may have been necessary in the beginning, and even one he was forced to pursue because others did not believe in what he was doing. Now it is apparent that there are a lot of people who believe. It looks like a few people working in a small lab are going to be overtaken by events. The suggestion of looking for collaborators seems like a good one. Perhaps someone involved in the research we read about would consider moving to a corporate position from an academic one if stock options were extended. If the group we read about has published Anil will be able to access their research. It would seem that if that were possible it could help to confirm his own findings in regard to methodology. That may solidify his choice for a candidate moving forward. If they don't move soon the game is up. The trading volume and the SP mean something.